How was published evidence used in model-based cost-utility analysis for lung cancer?
This study highlights challenges in parameter citation and the use of data inconsistent with the target disease and region in model-based CUAs. Enhancing transparency requires direct citation of original studies and generation of disease- and region-specific data to support robust economic evaluations.
Authors
- Ruowei Xiao (ORCID: https://orcid.org/0000-0003-1444-828X)
- Zhigang Zhao (ORCID: https://orcid.org/0000-0001-6258-2331)
- Hongting Nie
- Ting Zhou (ORCID: https://orcid.org/0000-0002-0049-4595)
- Wěi Li (ORCID: https://orcid.org/0000-0002-9522-4474)
- Yanan Xu (ORCID: https://orcid.org/0000-0002-0091-9709)
- Chunping Wang (ORCID: https://orcid.org/0000-0001-5694-2484)
- Sheng Han (ORCID: https://orcid.org/0000-0001-5975-3574)
- Haijing Guan
- Feng Xie (ORCID: https://orcid.org/0000-0003-3454-6266)
Institutions
- China Pharmaceutical University (CN)
- Capital Medical University (CN)
- Peking University (CN)
- Fudan University (CN)
- National Health and Family Planning Commission (CN)
- Beijing Tian Tan Hospital (CN)
- The Centre for Health (New Zealand) (NZ)
- Beijing Children’s Hospital (CN)
- Hamilton Health Sciences (CA)
Publication Details
- Journal
- Health Economics Review
- Published
- 2025-06-16
- DOI
- https://doi.org/10.1186/s13561-025-00651-6
- Primary Topic
- Health Systems, Economic Evaluations, Quality of Life
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- National Natural Science Foundation of China